Invesco Biotechnology & Genome ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.
Invesco Biotechnology & Genome ETF PBE
Morningstar’s Analysis PBE
Will PBE outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 49.5
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Natera Inc | 5.99 | 26M | Healthcare |
Illumina Inc | 5.91 | 26M | Healthcare |
Biogen Inc | 5.47 | 24M | Healthcare |
Gilead Sciences Inc | 5.22 | 23M | Healthcare |
Royalty Pharma PLC Class A | 4.98 | 21M | Healthcare |
Amgen Inc | 4.93 | 21M | Healthcare |
Regeneron Pharmaceuticals Inc | 4.81 | 21M | Healthcare |
Vertex Pharmaceuticals Inc | 4.62 | 20M | Healthcare |
Moderna Inc | 4.13 | 18M | Healthcare |
Novavax Inc | 3.28 | 14M | Healthcare |